Moderna MRNA shares are trading higher on Thursday amid growing concerns of U.S. coronavirus cases. Dr. Anthony Fauci earlier said the company will likely be going into advanced Phase 3 trials by the end of July.
Moderna is engaged in creating transformative medicines based on messenger RNA, or mRNA. It transfers the information stored in the genes to the cellular machinery that makes all the proteins required for life. The firm is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases.
Moderna shares were trading up 5.17% at $64.76 at the time of publication on Thursday. The stock has a 52-week high of $87 and a 52-week low of $11.54.
See Also:
Moderna Strikes Another Coronavirus Vaccine Manufacturing Deal To Ensure Overseas Supply
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
